Aurobindo Pharma Limited has informed the Exchange about completion of US FDA Inspection at Unit-V of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma has informed the stock exchange that the US FDA has completed its inspection at Unit-V of Apitoria Pharma Private Limited, which is a wholly owned subsidiary of the company. No further details regarding the classification or outcome of the inspection (such as Form 483 observations or Official Action Indicated status) have been disclosed in this filing. The announcement is a routine regulatory compliance update. Investors will await the inspection classification to assess any potential impact on production or approvals from this facility.
Neutral to slightly positive in the short term as completion without immediate adverse news removes uncertainty; however, the actual impact depends on the inspection classification, which has not yet been disclosed. Shareholders should watch for follow-up filings regarding Form 483 or EIR status.